Nevro is a company.
Nevro has raised $134.0M across 4 funding rounds.
Key people at Nevro.
Nevro has raised $134.0M in total across 4 funding rounds.
Key people at Nevro.
Nevro Corp is a medical device company headquartered in Redwood City, California, specializing in innovative spinal cord stimulation (SCS) therapies for chronic pain management, particularly of the trunk and limbs.[1][2][4] It develops the HFX platform, including the Senza SCS System delivering 10 kHz Therapy, which provides evidence-based pain relief without paresthesia (unpleasant tingling sensations common in traditional SCS).[1][3][4] Nevro serves patients with conditions like painful diabetic neuropathy (PDN), non-surgical back pain (NSBP), and chronic back/leg pain, addressing limitations of legacy SCS therapies over 30 years old by offering superior long-term outcomes, as designated by the FDA.[1][3][5] Founded in 2006 as a public company with 1,215 employees and $425.2 million in 2023 revenue, Nevro has treated tens of thousands worldwide and recently merged with Globus Medical to expand treatment options.[2]
Nevro was founded in 2006 in Redwood City, California, with a mission to disrupt traditional SCS by pioneering 10 kHz Therapy for chronic pain relief.[1][2][4] The company's foundational innovation, the Senza SCS System, earned CE mark approval in Europe in 2010, followed by FDA approval in the U.S. in 2015, and uniquely received FDA designation as superior to traditional SCS for back and leg pain.[1][3][4] Early commercialization began in Europe and Australia in 2011, building traction through clinical evidence showing significant pain reduction and improved daily function for patients.[1][3] Key milestones include expanding HFX to all SCS frequencies and waveforms in a single U.S.-approved product, while recent developments like the 2024 merger with Globus Medical mark a pivotal evolution toward broader pain management integration.[2]
Nevro stands out in the medtech space through clinically validated innovations and patient-centric design:
Nevro rides the wave of precision neuromodulation and AI-enhanced medtech, capitalizing on rising chronic pain prevalence driven by aging populations, diabetes surges, and opioid alternatives amid public health crises.[1][2][5][6] Its timing aligns with FDA expansions for PDN/NSBP and post-2015 approvals, fueling adoption in a $5B+ SCS market where legacy tech lagged.[3][4] Favorable forces include growing evidence demands, reimbursement gains, and the 2024 Globus merger, amplifying distribution and R&D for integrated spine solutions.[2] Nevro influences the ecosystem by setting benchmarks for paresthesia-free therapy, inspiring competitors, and enabling physicians to achieve better outcomes, thus accelerating non-opioid pain management standards.[1][5]
Post-merger with Globus Medical, Nevro's trajectory points to accelerated global expansion, deeper AI personalization in HFX, and new indications leveraging combined portfolios for holistic spine/pain care.[2][6] Trends like wearable neuromodulation, real-world data analytics, and value-based healthcare will propel growth, potentially doubling access amid 100M+ U.S. chronic pain sufferers. Its influence may evolve from disruptor to market leader, transforming lives through evidence-driven relief as in its founding vision.[1]
Nevro has raised $134.0M in total across 4 funding rounds.
Nevro's investors include Canaan Partners, Johnson & Johnson Innovation, Pivotal bioVenture Partners, Aberdare Ventures, Acorn Bioventures, Highbury Group.
Nevro has raised $134.0M across 4 funding rounds. Most recently, it raised $48.0M Series C in March 2013.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Mar 1, 2013 | $48.0M Series C | Canaan Partners, Johnson & Johnson Innovation, Pivotal bioVenture Partners | |
| Jul 1, 2011 | $58.0M Series B | Aberdare Ventures, Acorn Bioventures, Highbury Group, Johnson & Johnson Innovation | |
| Sep 1, 2008 | $22.0M Series A | Aberdare Ventures, Acorn Bioventures, Highbury Group | |
| Dec 1, 2006 | $6.0M Seed | Aberdare Ventures, Acorn Bioventures, Highbury Group |
